A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

Key Inclusion Criteria: * A clinical diagnosis of moderate to severe COPD according to the following criteria: * Current or ex-smokers with at least 10 pack-year smoking history * Post-bronchodilator FEV1 \>/= 35% and \</= 80% of predicted normal value * Post-bronchodilator FEV1/FVC (forced vital capacity) ratio \<0.70 * Post-bronchodilator improvement in FEV1 \>/= 100 mL Key Exclusion Criteria: * Current evidence or recent history of clinically significant or unstable disease (other than COPD) * Current diagnosis of asthma * Presence of history of clinically significant allergy requiring treatment * COPD exacerbation within 6 weeks * Use of daily oxygen therapy \> 10 hours * Thoracotomy with pulmonary resection * Use of systemic steroids within 3 months * Lower respiratory tract infection within 30 days * Upper respiratory tract infection within 30 days requiring treatment with antibiotics * History of tuberculosis, bronchiectasis, or other non-specific pulmonary disease * Prolonged corrected QT (QTc) interval \>450 msec males and \>470 msec females, or history of long QT syndrome